Polaryx Therapeutics appointed Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to its Board of Directors effective January 29, 2026.
Andrew O ceased serving as a Board member on the same date.
The new members bring expertise in scientific research, clinical development, finance, and corporate strategy.
Appointments announced publicly on February 5, 2026.
Polaryx is advancing its lead candidate PLX-200 into an IND-approved SOTERIA Phase 2 basket trial.